Recent News

• 04.23.2025 - Tiziana Life Sciences Announces University of Massachusetts Commences Dosing Intranasal Foralumab in Phase 2 Multiple Sclerosis Trial
• 04.23.2025 - Tiziana Life Sciences Announces University of Massachusetts Commences Dosing Intranasal Foralumab in Phase 2 Multiple Sclerosis Trial
• 04.23.2025 - Tiziana Life Sciences Announces University of Massachusetts Commences Dosing Intranasal Foralumab in Phase 2 Multiple Sclerosis Trial
• 04.23.2025 - Tiziana Life Sciences Announces University of Massachusetts   Commences Dosing Intranasal Foralumab in Phase 2 Multiple Sclerosis Trial
• 04.02.2025 - Tiziana Life Sciences Announces Johns Hopkins University Commences Dosing Nasal Foralumab in Phase 2 Multiple Sclerosis Clinical Trial
• 04.02.2025 - Tiziana Life Sciences Announces Johns Hopkins University Commences Dosing Nasal Foralumab in Phase 2 Multiple Sclerosis Clinical Trial
• 04.02.2025 - Tiziana Life Sciences Announces Johns Hopkins University Commences Dosing Nasal Foralumab in Phase 2 Multiple Sclerosis Clinical Trial
• 04.02.2025 - Tiziana Life Sciences Announces Johns Hopkins University Commences Dosing Nasal Foralumab in Phase 2 Multiple Sclerosis Clinical Trial
• 03.25.2025 - Tiziana Life Sciences Announces Yale University Commences Intranasal Foralumab Dosing in Phase 2 Multiple Sclerosis Trial
• 03.25.2025 - Tiziana Life Sciences Announces Yale University Commences Intranasal Foralumab Dosing in Phase 2 Multiple Sclerosis Trial

Recent Filings

• 04.02.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 04.02.2025 - EX-99.1 EX-99.1
• 03.27.2025 - EFFECT Notice of Effectiveness
• 03.25.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 03.25.2025 - EX-99.1 EX-99.1
• 03.24.2025 - F-3 Registration statement by foreign private issuers